MX2021007076A - Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. - Google Patents
Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.Info
- Publication number
- MX2021007076A MX2021007076A MX2021007076A MX2021007076A MX2021007076A MX 2021007076 A MX2021007076 A MX 2021007076A MX 2021007076 A MX2021007076 A MX 2021007076A MX 2021007076 A MX2021007076 A MX 2021007076A MX 2021007076 A MX2021007076 A MX 2021007076A
- Authority
- MX
- Mexico
- Prior art keywords
- cannabidiol
- deletion syndrome
- treatment
- subject
- behavioral symptoms
- Prior art date
Links
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 title abstract 3
- 208000000398 DiGeorge Syndrome Diseases 0.000 title abstract 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 3
- 229950011318 cannabidiol Drugs 0.000 title abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 3
- 208000013404 behavioral symptom Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente tecnología se refiere a los métodos para el tratamiento de uno o más síntomas del comportamiento (por ejemplo, ansiedad) del síndrome de supresión del 22q11.2 en un sujeto por medio de la administración, por ejemplo, de manera transdérmica, de una cantidad eficaz de cannabidiol (CBD, por sus siglas en inglés) al sujeto, en donde se tratan en el sujeto uno o más de los síntomas del comportamiento del síndrome de supresión del 22q11.2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779591P | 2018-12-14 | 2018-12-14 | |
| US201962895279P | 2019-09-03 | 2019-09-03 | |
| PCT/IB2019/060735 WO2020121260A1 (en) | 2018-12-14 | 2019-12-12 | Treatment of 22q11.2 deletion syndrome with cannabidiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007076A true MX2021007076A (es) | 2021-08-11 |
Family
ID=69137939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007076A MX2021007076A (es) | 2018-12-14 | 2019-12-12 | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
| MX2024003145A MX2024003145A (es) | 2018-12-14 | 2021-06-14 | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003145A MX2024003145A (es) | 2018-12-14 | 2021-06-14 | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11458109B2 (es) |
| EP (1) | EP3893858A1 (es) |
| KR (1) | KR20210104084A (es) |
| AU (1) | AU2019396750A1 (es) |
| BR (1) | BR112021011279A2 (es) |
| CA (1) | CA3122735A1 (es) |
| IL (1) | IL283929A (es) |
| JO (1) | JOP20210140A1 (es) |
| MX (2) | MX2021007076A (es) |
| WO (1) | WO2020121260A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62969B1 (sr) | 2017-09-28 | 2022-03-31 | Zynerba Pharmaceuticals Inc | Lečenje fragilnog x sindroma i autizma kanabidiolom |
| CA3122735A1 (en) | 2018-12-14 | 2020-06-18 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| US20230000792A1 (en) * | 2018-12-14 | 2023-01-05 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| JP7670700B2 (ja) | 2019-10-11 | 2025-04-30 | パイク セラピューティクス インコーポレイテッド | 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物 |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| AU2020366147B2 (en) | 2019-10-14 | 2024-09-05 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| FI20020333A0 (fi) | 2002-02-20 | 2002-02-20 | Tomi Jaervinen | Metyloidun syklodekstriinin uudet kompleksit |
| TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| WO2008060375A2 (en) | 2006-10-06 | 2008-05-22 | The Regents Of The University Of Californina | Upregulating bdnf levels to mitigate mental retardation |
| MX2010001242A (es) | 2007-07-30 | 2010-07-02 | Alltranz Inc | Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos. |
| US20100273895A1 (en) | 2009-04-28 | 2010-10-28 | Alltranz Inc. | Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same |
| DK2473475T3 (en) | 2009-08-31 | 2017-06-26 | Zynerba Pharmaceuticals Inc | APPLICATION OF CANNABIDIOL PRODUCTS IN TOPIC AND TRANSDERMAL MICROWAVE ADMINISTRATION |
| ES2894836T3 (es) | 2013-01-08 | 2022-02-16 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Compuestos de CBD fluorados, composiciones y usos de los mismos |
| WO2015065179A1 (en) | 2013-10-29 | 2015-05-07 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
| US20160022627A2 (en) | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| WO2015184127A2 (en) | 2014-05-29 | 2015-12-03 | Insys Pharma, Inc. | Stable cannabinoid formulations |
| US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| US20160271252A1 (en) | 2014-05-29 | 2016-09-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| ES2877361T3 (es) | 2014-06-27 | 2021-11-16 | Farm To Farma Inc | Formulaciones de cannabinoides bucales y sublinguales y método para hacer las mismas |
| US20160000843A1 (en) | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| PH12021551869A1 (en) | 2014-10-21 | 2022-06-27 | United Cannabis Corp | Cannabis extracts and methods of preparing and using same |
| US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
| US20190125779A1 (en) | 2014-12-30 | 2019-05-02 | University Of Houston System | Pharmaceutical compositions |
| US20160256410A1 (en) | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
| US20160338974A1 (en) | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
| WO2017068349A1 (en) * | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| EP3423047A4 (en) | 2016-03-04 | 2020-01-01 | Sharon Anavi-Goffer | Compositions of cb2 receptor selective agonists for treatment of mental disorders |
| IL301006A (en) | 2016-03-16 | 2023-04-01 | Buzzelet Development And Technologies Ltd | Cannobinoid compounds are rich in terpenes |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| CA3021144C (en) | 2016-04-19 | 2024-04-09 | Canabuzz-Med | Cannabis-enriched enzymatically treated therapeutic composition |
| TWI790204B (zh) | 2016-06-02 | 2023-01-21 | 加拿大商阿爾宙斯製藥有限公司 | 鼻用大麻素組成物 |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| IL246790A0 (en) | 2016-07-14 | 2016-09-29 | Friedman Doron | Self-dissolving compounds of cannabinoids |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| CN107126411A (zh) | 2017-03-22 | 2017-09-05 | 哈尔滨惠美佳生物科技有限公司 | 具有缓解神经性头痛作用的大麻二酚凝胶及其制备方法 |
| BR112020003025A2 (pt) | 2017-08-14 | 2020-08-04 | Zynerba Pharmaceuticals, Inc. | métodos de tratamento de osteoartrite com gel transdérmico de canabidiol |
| EP3681525A4 (en) | 2017-09-15 | 2020-09-02 | Zelda Therapeutics Operations Pty Ltd | COMPOSITION AND METHOD OF PROCESSING AUTISM |
| US20230059709A1 (en) | 2017-09-28 | 2023-02-23 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome with cannabidiol |
| RS62969B1 (sr) | 2017-09-28 | 2022-03-31 | Zynerba Pharmaceuticals Inc | Lečenje fragilnog x sindroma i autizma kanabidiolom |
| CA3080434A1 (en) | 2017-10-30 | 2019-05-09 | Endocanna Health, Inc. | Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations |
| CA3101334A1 (en) | 2018-05-24 | 2019-11-28 | To Pharmaceuticals Llc | Cannabis-based compositions for the treatment of autistic spectrum disorders |
| CA3122735A1 (en) * | 2018-12-14 | 2020-06-18 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| KR20230016003A (ko) | 2020-05-26 | 2023-01-31 | 지네르바 파마슈티컬스, 인코포레이티드 | 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료 |
| MX2022016536A (es) | 2020-06-29 | 2023-03-15 | Zynerba Pharmaceuticals Inc | Tratamiento del síndrome de x frágil con cannabidiol. |
| GB2597322A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
-
2019
- 2019-12-12 CA CA3122735A patent/CA3122735A1/en active Pending
- 2019-12-12 KR KR1020217021748A patent/KR20210104084A/ko active Pending
- 2019-12-12 AU AU2019396750A patent/AU2019396750A1/en active Pending
- 2019-12-12 JO JOP/2021/0140A patent/JOP20210140A1/ar unknown
- 2019-12-12 WO PCT/IB2019/060735 patent/WO2020121260A1/en unknown
- 2019-12-12 BR BR112021011279-0A patent/BR112021011279A2/pt unknown
- 2019-12-12 EP EP19832440.2A patent/EP3893858A1/en active Pending
- 2019-12-12 US US16/712,066 patent/US11458109B2/en active Active
- 2019-12-12 MX MX2021007076A patent/MX2021007076A/es unknown
-
2021
- 2021-06-13 IL IL283929A patent/IL283929A/en unknown
- 2021-06-14 MX MX2024003145A patent/MX2024003145A/es unknown
-
2022
- 2022-09-30 US US17/957,932 patent/US12186282B2/en active Active
-
2024
- 2024-12-05 US US18/970,458 patent/US20250205174A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011279A2 (pt) | 2021-08-31 |
| KR20210104084A (ko) | 2021-08-24 |
| EP3893858A1 (en) | 2021-10-20 |
| MX2024003145A (es) | 2024-04-15 |
| US20230024756A1 (en) | 2023-01-26 |
| CA3122735A1 (en) | 2020-06-18 |
| US20200188324A1 (en) | 2020-06-18 |
| US12186282B2 (en) | 2025-01-07 |
| JOP20210140A1 (ar) | 2023-01-30 |
| IL283929A (en) | 2021-07-29 |
| AU2019396750A1 (en) | 2021-07-08 |
| WO2020121260A1 (en) | 2020-06-18 |
| US11458109B2 (en) | 2022-10-04 |
| US20250205174A1 (en) | 2025-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007076A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| JOP20200082A1 (ar) | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| MX2015010191A (es) | Metodos para tratar infecciones microbianas, incluyendo mastitis. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| BR112022007523A2 (pt) | Limpeza e despoluição de fibras originadas a partir de pontas de cigarro usadas pelo contato com um fluido supercrítico e reciclagem das fibras despoluídas | |
| JOP20220310A1 (ar) | علاج اضطراب طيف التوحد بكانابيديول | |
| MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| MX2019012659A (es) | Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| CR20220006A (es) | Compuestos para tratar enfermedad respiratoria | |
| CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| WO2020021332A3 (en) | Injection techniques for the treatment of cellulite | |
| MX378093B (es) | Composiciones para usarse en el tratamiento de linfoma cutáneo de células t. |